Skip to Content
Merck
All Photos(2)

Documents

M3047

Sigma-Aldrich

Mizoribine

≥98% (TLC)

Synonym(s):

N′-(β-D-Ribofuranosyl)-5-hydroxy­imida­zole-4-carboxamide

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C9H13N3O6
CAS Number:
50924-49-7
Molecular Weight:
259.22
MDL number:
MFCD00057221
UNSPSC Code:
12352200
PubChem Substance ID:
24278546
NACRES:
NA.77

Quality Level

200

Assay

≥98% (TLC)

storage temp.

2-8°C

SMILES string

NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O

InChI

1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1

InChI key

HZQDCMWJEBCWBR-UUOKFMHZSA-N

Application

Mizoribine has been used in topical treatment to evaluate its effect on ocular surface damage of dry eye in B6 mice subjected to desiccating stress (DS). It has also been used as an inosine monophosphate dehydrogenase (IMPDH) inhibitor to test its in vivo efficacy.

Biochem/physiol Actions

Mizoribine is an imidazole nucleoside possessing strong immunosuppressive properties. It selectively blocks T-cell proliferation response to mitogenic and allo-antigenic stimulation. Mizoribine blocks the movement of T cells from G to S phase. In addition, it significantly decreases the number of B cells at the S, G, and M phases. Mizoribine inhibits de novo synthesis of nucleotides by inhibition of inosine monophosphate dehydrogenase. The resulting nucleotide depletion inhibits DNA synthesis.(3)

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H315,H319,H335,H360

Hazard Classifications

Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A Nomura et al.
Lupus, 21(13), 1444-1449 (2012-08-25)
The prognosis of lupus nephritis (LN) has improved since the introduction of immunosuppressant therapies, but the safety and effectiveness of treatments can also be improved. We retrospectively assessed the treatment courses of 12 patients with systemic lupus erythematosus who were
Larry A Greenbaum et al.
Nature reviews. Nephrology, 8(8), 445-458 (2012-06-13)
The introduction of corticosteroids more than 50 years ago dramatically improved the prognosis of children with nephrotic syndrome. Corticosteroids remain the standard initial treatment for children with this disease, but a considerable proportion of patients do not respond and are
Hideaki Yamabe et al.
Biological & pharmaceutical bulletin, 35(5), 705-708 (2012-06-13)
Glomerular crescents play an important role in progressive glomerular injury. The lesions consist of epithelial cells, macrophages and fibrin deposition. Macrophage chemoattractant protin-1 (MCP-1) is a chemoattractant of monocytes, which has a potential of procoagulant activity. Macrophage inflammatory protein-2 (MIP-2)
Maintenance therapy with single-daily, high-dose mizoribine after cyclophosphamide therapy for prepubertal boys with severe steroid-dependent nephrotic syndrome.
Shuichiro Fujinaga et al.
Clinical nephrology, 78(3), 251-252 (2012-05-01)
Takashi Hashimoto et al.
Dermatologic therapy, 25(4), 382-385 (2012-09-07)
We evaluated the effectiveness of mizoribine, a newly developed immunosuppressive agent, as an adjuvant therapy in the treatment of both pemphigus vulgaris and pemphigus foliaceus. Eleven pemphigus patients (eight pemphigus vulgaris and three pemphigus foliaceus) received the combination therapy of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service